1,11-Bis(4-formylphenoxy)undecane | 90076-73-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1,11-Bis(4-formylphenoxy)undecane
• 英文别名: 4-[11-(4-Formylphenoxy)undecoxy]benzaldehyde
• CAS: 90076-73-6
• 化学式: C₂₅H₃₂O₄
• 分子量: 396.527
• InChiKey: MAEMYGBICFHWEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  29
• 可旋转键数：
  16
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,11-Bis(4-formylphenoxy)undecane 在 sodium tetrahydroborate 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 4.0h， 生成 4,4'-[undecane-1,11-diylbis(oxy)]bis[benzenemethanol]
  参考文献：
  名称：

  27 至 39 位吡啶大环化合物

  摘要：

  已经通过威廉姆森醚合成或闭环复分解合成了一组 27 至 39 元吡啶大环 2 和 3。吡啶是 2,6-二取代的以允许内相互作用。除了长度之外，脂肪链的性质也不同：饱和（2）和不饱和（3）。

  DOI：

  10.1002/ejoc.201000505
• 作为产物：
  描述：

  1,11-二溴十一烷 、 对羟基苯甲醛 在 potassium carbonate 、 sodium iodide 作用下， 以 丁酮 为溶剂， 生成 1,11-Bis(4-formylphenoxy)undecane
  参考文献：
  名称：

  27 至 39 位吡啶大环化合物

  摘要：

  已经通过威廉姆森醚合成或闭环复分解合成了一组 27 至 39 元吡啶大环 2 和 3。吡啶是 2,6-二取代的以允许内相互作用。除了长度之外，脂肪链的性质也不同：饱和（2）和不饱和（3）。

  DOI：

  10.1002/ejoc.201000505

文献信息

• Symmetric and non-symmetric liquid crystal dimers with branched terminal alkyl chains: racemic and chiral
  作者：Andrew E. Blatch、Ian D. Fletcher、Geoffrey R. Luckhurst

  DOI：10.1039/a602980i

  日期：——

  Two new series of racemic dimeric liquid crystals containing terminal alkyl chains with methyl branches are presented; in one the dimers are symmetric and in the other they are non-symmetric. Comparisons are made with the structurally isomeric series with no methyl branches in their terminal alkyl chains. The stability and clearing temperatures of the liquid crystal phases are markedly reduced for the dimers with methyl branches, particularly for the symmetric dimers. Chiral analogues of both series were also examined. The liquid crystal behaviour of the non-symmetric dimers is of particular interest. Four homologues were studied with the number of methylene units in the spacer ranging from six to nine. An odd–even effect was observed for the chiral properties of these materials. Blue phase I behaviour was exhibited by the heptane and nonane homologues but not by the even membered hexane and octane members of the series.

  本文介绍了两个新的外消旋二聚液晶系列，其中一个系列中的二聚物是对称的，另一个系列中的二聚物是不对称的。并与末端烷基链中没有甲基分支的结构异构系列进行了比较。有甲基支链的二聚体，尤其是对称二聚体，液晶相的稳定性和清澈温度明显降低。我们还研究了这两个系列的手性类似物。非对称二聚体的液晶行为尤其引人关注。我们研究了四种同系物，其间隔中亚甲基单位的数量从六个到九个不等。观察到这些材料的手性具有奇偶效应。该系列中的庚烷和壬烷同系物表现出蓝色 I 相行为，而偶数成员的己烷和辛烷则没有。
• NOVEL BISOXADIAZOLIDINE DERIVATIVE
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0696585A1

  公开（公告）日：1996-02-14

  A bisoxadiazolidinedione derivative of general formula (I) useful as an insulin-sensitivity improver, a pharmaceutically acceptable salt thereof, and a medicinal composition thereof, wherein (a) and (b) may be the same or different from each other and each represent an optionally substituted phenylene group, and L represents: (1) an oxygen atom, (2) a group of formula (II) (R¹ being a hydrogen atom or a lower alkyl group), (3) a group of the formula: -S(O)n- (n being 0, 1 or 2), (4) a group of the formula: -CO-, (5) a group of formula (III) or (IV) (R² being a hydrogen atom or a lower alkyl group), or (6) an alkylene or alkenylene group which may be substituted and interrupted by an oxygen atom and/or a sulfur atom, and the like.

  一种用作胰岛素敏感性改善剂的通式(I)的双噁二唑烷二酮衍生物、其药学上可接受的盐及其药物组合物，其中(a)和(b)可以相同或互不相同，且各自代表任选取代的亚苯基，L代表：(1) 氧原子，(2) 式 (II) 的基团（R¹ 为氢原子或低级烷基），(3) 式中的基团：-S(O)n-（n 为 0、1 或 2），(4) 式中的一个基团：-CO-，(5)式(III)或(IV)的基团（R²为氢原子或低级烷基），或(6)可被氧原子和/或硫原子取代和间断的亚烷基或烯基等。
• Griffin; Britt; Hung, Molecular Crystals and Liquid Crystals (1969-1991), 1983, vol. 105, # 1-4, p. 305 - 314
  作者：Griffin、Britt、Hung、Steele

  DOI：——

  日期：——
• Biological evaluation of bisbenzaldehydes against four Mycobacterium species
  作者：Davie Cappoen、Delphine Forge、Frank Vercammen、Vanessa Mathys、Mehdi Kiass、Virginie Roupie、Roel Anthonissen、Luc Verschaeve、Jean Jacques Vanden Eynde、Kris Huygen

  DOI：10.1016/j.ejmech.2013.03.023

  日期：2013.5

  A series of bisbenzaldehydes and structurally related analogs, conveniently synthesized via microwave-assisted reactions, were evaluated in vitro against drug susceptible and multi-drug resistant Mycobacterium tuberculosis, against virulent Mycobacterium bovis, against Mycobacterium ulcerans and against two Mycobacterium avium subspecies. Among the 33 substances that were tested, compound 12, i.e. 4,4'-[1,12-dodecanediyl(oxy)]bisbenzaldehyde, emerged as the most promising hit. Its activity was further confirmed in an intracellular growth inhibition assay of M. tb in murine J774 A.1 macrophages. None of the compounds showed significant cytotoxicity on human C3A hepatocytes in a neutral red dye uptake assay and no genotoxicity or mutagenicity was observed as demonstrated by a VITOTOX (TM) test and confirmed with a comet assay. (C) 2013 Elsevier Masson SAS. All rights reserved.
• FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS
  申请人：Arbiser Jack L.

  公开号：US20080275016A1

  公开（公告）日：2008-11-06

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.